RO7079901

Phase 1Small molecule

Roche

RO7079901 is one of 37 small molecule programs targeting Urinary Tract Infection. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Urinary Tract InfectionActive, not recruiting

Urinary Tract InfectionPhase 1

Active, not recruiting

Competition

Competitive Landscape

163 competitors in Urinary Tract Infection

#DrugCompanyPhaseTrials

Maxipime

Pfizer

Phase 3

3 2

Merrem

BB. Braun Medical Inc.

Phase 3

7 3

Rocephin

CConrado Roberto Hoffmann Filho

Phase 3

2 4

Comparator: Pbo

Merck & Co.

Phase 3

2 5

Prulifloxacin

Merck & Co.

Phase 3

1 6

Piperacillin/tazobactam

Pfizer

Phase 3

1 7

Amoxicillin/clavulanate Potassium

Johnson & Johnson

Phase 3

1 8

Blujepa

GGlaxo Dba Glaxosmithkline

Phase 3

5 9

Amoxicillin/clavulanate

Bayer

Phase 3

1 10

Imipenem+cilastatin/relebactam

Merck & Co.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Urinary Tract Infection1 trial

A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection

Completed· Roche logo

Roche·Phase 1·NCT03174795·20 enrolled

Meropenem1 trial

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7079901 and the Combination of RO7079901 With Meropenem in Adult Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT02972255·46 enrolled

Hemodialysis1 trial

A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901

Completed· Roche logo

Roche·Phase 1·NCT02975388·29 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for RO7079901. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RO7079901 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RO7079901. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Roche

RO7079901

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Urinary Tract Infection1 trial

Meropenem1 trial

Hemodialysis1 trial

References

Drug Info

Quick Facts

Related News